Compare ARK Space & Defense Innovation ETF (ARKX) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Space & Defense Innovation ETF vs Novartis AG — how do they compare? ARK Space & Defense Innovation ETF trades at $34.43, while Novartis AG trades at $154.71 (market cap $298.18B). The key difference: Novartis AG pays a 3.02% dividend while ARK Space & Defense Innovation ETF pays none. Which is the better fit depends on your goals.
| ARKX | NVS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $37.74 | $168.62 |
52-Week Low | $25.46 | $119.31 |
Market Cap | — | $298.18B |
Enterprise Value | — | $339.50B |
Dividend Yield | — | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKX trades at $34.27, up 3.82% today, with a bullish technical signal from moving averages and ADX indicators, though RSI_6 suggests overbought conditions. The ETF focuses on space exploration and innovation, holding positions in companies like SpaceX and Rocket Lab, benefiting from strong sector tailwinds and recent SpaceX IPO momentum.
Outlook is positive due to growth in the space economy, but risks include high volatility and stretched valuations in key holdings. Investors should weigh exposure to speculative tech against potential regulatory and competitive pressures in the evolving market.
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Space & Defense Innovation ETF
ARKX is an actively managed ETF that invests in companies leading space exploration and defense innovation. It focuses on orbital and sub-orbital aerospace, reusable rockets, and enabling technologies like AI, robotics, and satellite systems.
Read more on ARKX →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
